Progressive bone loss in osteoporosis results from bone resorption in excess of bone formation. We conducted a double-blind study in 66 women with postmenopausal osteoporosis of therapy with etidronate, a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity. The patients were randomly assigned in equal numbers to receive oral etidronate (400 mg per day) or placebo for 2 weeks, followed by a 13-week period in which no drugs were given. This sequence was repeated 10 times, for a total of 150 weeks. Daily oral supplementation with calcium and vitamin D was given throughout the study to both groups. Vertebral bone mineral content was measured by dual-photon absorptiometry; spinal radiographs were assessed to identify new vertebral fractures. Vertebral bone mineral content increased significantly (P less than 0.01) after 150 weeks of etidronate therapy (5.3 percent; 95 percent confidence interval, 2.0 to 8.6; n = 20) but decreased with placebo (-2.7 percent; 95 percent confidence interval, -7.3 to 1.9; n = 20). The difference between groups was 8.0 percentage points (P less than 0.01; 95 percent confidence interval, 2.4 to 13.6). The rates of fracture were significantly different for the period from week 60 to week 150 between the etidronate and placebo groups (6 vs. 54 fractures per 100 patient-years; P = 0.023). No adverse clinical, biochemical, or bone histomorphometric effects of treatment were observed. We conclude that at the end of nearly three years, etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.
Source Information
Department of Medicine, Sundby Hospital, Copenhagen, Denmark.
This article has been cited by other articles:
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., BARNETT, B. L., COXON, F. P., ROGERS, M. J., WATTS, N. B., EBETINO, F. H.
(2007). Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy. Ann. N. Y. Acad. Sci.
1117: 209-257
[Abstract][Full Text]
ISALES, C. M., MCDONALD, J. M.
(2007). Future Developments in Therapy. Ann. N. Y. Acad. Sci.
1117: 258-263
[Abstract][Full Text]
Blake, G. M, Fogelman, I.
(2007). The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad. Med. J.
83: 509-517
[Abstract][Full Text]
Russell, R. G. G.
(2007). Bisphosphonates: Mode of Action and Pharmacology. Pediatrics
119: S150-S162
[Abstract][Full Text]
RUSSELL, R. G. G.
(2006). Bisphosphonates: From Bench to Bedside. Ann. N. Y. Acad. Sci.
1068: 367-401
[Abstract][Full Text]
Karlsson, M. K., Gerdhem, P., Ahlborg, H. G.
(2005). The prevention of osteoporotic fractures. J Bone Joint Surg Br
87-B: 1320-1327
[Full Text]
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., Orwoll, E., Yuen, C. K.
(2005). Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocr. Rev.
26: 688-703
[Abstract][Full Text]
Morris, C. D., Einhorn, T. A.
(2005). Bisphosphonates in Orthopaedic Surgery. JBJS
87: 1609-1618
[Abstract][Full Text]
Campbell, I A, Douglas, J G, Francis, R M, Prescott, R J, Reid, D M
(2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax
59: 761-768
[Abstract][Full Text]
Francis, R.M., Baillie, S.P., Chuck, A.J., Crook, P.R., Dunn, N., Fordham, J.N., Kelly, C., Rodgers, A.
(2004). Acute and long-term management of patients with vertebral fractures. QJM
97: 63-74
[Abstract][Full Text]
Woolf, A. D, Akesson, K.
(2003). Preventing fractures in elderly people. BMJ
327: 89-95
[Full Text]
Brown, T. E. R.
(2003). Osteoporosis: A Pharmacotherapy Update. Journal of Pharmacy Practice
16: 164-169
[Abstract]
Brown, J. P., Josse, R. G.
(2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ
168: SF1-38
[Abstract][Full Text]
Brown, J. P., Josse, R. G.
(2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ
167: s1-34
[Abstract][Full Text]
Tuck, S P, Francis, R M
(2002). Osteoporosis. Postgrad. Med. J.
78: 526-532
[Abstract][Full Text]
Meunier, P. J., Slosman, D. O., Delmas, P. D., Sebert, J. L., Brandi, M. L., Albanese, C., Lorenc, R., Pors-Nielsen, S., De Vernejoul, M. C., Roces, A., Reginster, J. Y.
(2002). Strontium Ranelate: Dose-Dependent Effects in Established Postmenopausal Vertebral Osteoporosis--A 2-Year Randomized Placebo Controlled Trial. J. Clin. Endocrinol. Metab.
87: 2060-2066
[Abstract][Full Text]
Hodsman, A. B., Hanley, D. A., Josse, R.
(2002). Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ
166: 1426-1430
[Full Text]
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., Body, J.-J., Brandi, M. L., Broell, J., Di Micco, R., Genazzani, A. R., Felsenberg, D., Happ, J., Hooper, M. J., Ittner, J., Leb, G., Mallmin, H., Murray, T., Ortolani, S., Rubinacci, A., Saaf, M., Samsioe, G., Verbruggen, L., Meunier, P. J.
(2002). Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. NEJM
346: 653-661
[Abstract][Full Text]
Marcus, R., Wong, M., Heath, H. III, Stock, J. L.
(2002). Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. Endocr. Rev.
23: 16-37
[Abstract][Full Text]
Gehlbach, S. H., Fournier, M., Bigelow, C.
(2002). Recognition of Osteoporosis by Primary Care Physicians. Am. J. Public Health
92: 271-273
[Abstract][Full Text]
Mochida, Y., Bauer, T. W., Akisue, T., Brown, P. R.
(2002). Alendronate Does Not Inhibit Early Bone Apposition to Hydroxyapatite-Coated Total Joint Implants : A Preliminary Study. JBJS
84: 226-235
[Abstract][Full Text]
Wade, J. P.
(2001). Rheumatology: 15. Osteoporosis. CMAJ
165: 45-50
[Full Text]
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., Mitlak, B. H., Mellstrom, D., Oefjord, E. S., Marcinowska-Suchowierska, E., Salmi, J., Mulder, H., Halse, J., Sawicki, A. Z.
(2001). Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM
344: 1434-1441
[Abstract][Full Text]
Harris, S. T., Eriksen, E. F., Davidson, M., Ettinger, M. P., Moffett, A. H. Jr., Baylink, D. J., Crusan, C. E., Chines, A. A.
(2001). Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women. J. Clin. Endocrinol. Metab.
86: 1890-1897
[Abstract][Full Text]
Francis, R.M., Baillie, S.P., Chuck, A.J., Crook, P.R., Daymond, T., Dunn, N., Fordham, J.N., Kelly, C., Rodgers, A.
(2000). Management of osteoporosis in patients with hip fractures. QJM
93: 501-506
[Full Text]
Freedman, K. B., Kaplan, F. S., Bilker, W. B., Strom, B. L., Lowe, R. A.
(2000). Treatment of Osteoporosis: Are Physicians Missing an Opportunity?*{{dagger}}. JBJS
82: 1063-1063
[Abstract][Full Text]
Shaw, N J, Boivin, C M, Crabtree, N J
(2000). Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child.
83: 143-145
[Abstract][Full Text]
Pfeilschifter, J., Diel, I. J.
(2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO
18: 1570-1593
[Abstract][Full Text]
Wasnich, R. D., Miller, P. D.
(2000). Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density. J. Clin. Endocrinol. Metab.
85: 231-236
[Abstract][Full Text]
Scott, E M, Gaywood, I, Scott, B B
(2000). Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut
46: I1-8
[Full Text]
Srivastava, T., Alon, U. S.
(1999). Bisphosphonates: From Grandparents to Grandchildren. CLIN PEDIATR
38: 687-702
[Abstract]
Bucher, H. C., Guyatt, G. H., Cook, D. J., Holbrook, A., McAlister, F. A., for the Evidence-Based Medicine Working Group,
(1999). Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA
282: 771-778
[Full Text]
Geusens, P., Dequeker, J., Vanhoof, J., Stalmans, R., Boonen, S., Joly, J., Nijs, J., Raus, J.
(1998). Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis
57: 724-727
[Abstract][Full Text]
Masud, T, Mulcahy, B, Thompson, A V, Donnelly, S, Keen, R W, Doyle, D V, Spector, T D
(1998). Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis
57: 346-349
[Abstract][Full Text]
Torgerson, D. J, Dolan, P.
(1998). Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis
57: 378-379
[Abstract][Full Text]
Eastell, R.
(1998). Treatment of Postmenopausal Osteoporosis. NEJM
338: 736-746
[Full Text]
Hosking, D., Chilvers, C. E.D., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., Yates, A. J., The Early Postmenopausal Intervention Cohort Study,
(1998). Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age. NEJM
338: 485-492
[Abstract][Full Text]
Disla, E., Tamayo, B., Fahmy, A., Adachi, J. D., Pack, S., Chines, A. A.
(1997). Intermittent Etidronate and Corticosteroid-Induced Osteoporosis. NEJM
337: 1921-1921
[Full Text]
TOBIAS, J. H
(1997). How do bisphosphonates prevent fractures?. Ann Rheum Dis
56: 510-511
[Full Text]
Sato, Y., Maruoka, H., Oizumi, K.
(1997). Amelioration of Hemiplegia-Associated Osteopenia More Than 4 Years After Stroke by 1{alpha}-Hydroxyvitamin D3 and Calcium Supplementation. Stroke
28: 736-739
[Abstract][Full Text]
GEUSENS, P., VANHOOF, J., RAUS, J., DEQUEKER, J., NIJS, J., JOLY, J.
(1997). Treatment with etidronate for men with idiopathic osteoporosis. Ann Rheum Dis
56: 280a-280
[Full Text]
Hodsman, A. B., Fraher, L. J., Watson, P. H., Ostbye, T., Stitt, L. W., Adachi, J. D., Taves, D. H., Drost, D.
(1997). A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab.
82: 620-628
[Abstract][Full Text]
Bone, H. G., Downs, R. W. Jr., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., Polvino, W. J.
(1997). Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women. J. Clin. Endocrinol. Metab.
82: 265-274
[Abstract][Full Text]
Liberman, U. A., Weiss, S. R., Broll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., Lombardi, A., Shah, R. V., Hirsch, L. J., Karpf, D. B., The Alendronate Phase III Osteoporosis Treatment S,
(1995). Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. NEJM
333: 1437-1444
[Abstract][Full Text]
Laitinen, K.
(1995). Use individual event rate adjustment for follow up time. BMJ
310: 1469b-1470
[Full Text]
Windeler, J., Lange, S.
(1995). Events per person year--a dubious concept. BMJ
310: 454-456
[Full Text]
Compston, J E
(1994). Fortnightly Review: The therapeutic use of bisphosphonates. BMJ
309: 711-715
[Full Text]
(1990). ETIDRONATE MAY BE EFFECTIVE TREATMENT FOR OSTEOPOROSIS. JWatch General
1990: 2-2
[Full Text]
Previous
